Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Change in Accured Expenses (2018 - 2025)

Bicycle Therapeutics (BCYC) has disclosed Change in Accured Expenses for 8 consecutive years, with $1.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Accured Expenses fell 88.3% year-over-year to $1.1 million, compared with a TTM value of $5.8 million through Sep 2025, up 157.68%, and an annual FY2024 reading of $9.7 million, up 304.42% over the prior year.
  • Change in Accured Expenses was $1.1 million for Q3 2025 at Bicycle Therapeutics, down from $9.2 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $11.5 million in Q2 2023 and bottomed at -$8.2 million in Q1 2025.
  • Average Change in Accured Expenses over 5 years is $1.5 million, with a median of $1.3 million recorded in 2021.
  • The sharpest move saw Change in Accured Expenses crashed 300.43% in 2021, then skyrocketed 2687.8% in 2022.
  • Year by year, Change in Accured Expenses stood at $1.7 million in 2021, then soared by 302.52% to $6.9 million in 2022, then crashed by 153.68% to -$3.7 million in 2023, then surged by 201.63% to $3.7 million in 2024, then crashed by 70.07% to $1.1 million in 2025.
  • Business Quant data shows Change in Accured Expenses for BCYC at $1.1 million in Q3 2025, $9.2 million in Q2 2025, and -$8.2 million in Q1 2025.